School of Medicine
Showing 941-950 of 13,057 Results
-
Alice Bertaina MD, PhD
Lorry I. Lokey Professor
Current Research and Scholarly InterestsDr. Bertaina is a highly experienced clinician and will play a key role in supporting Section Chief Dr. Rajni Agarwal and Clinical Staff in the Stem Cell Transplant Unit at Lucile Packard Children’s Hospital. She will also continue her research on immune recovery and miRNA, understanding the mechanisms underlying immune reconstitution, Graft-versus-Host Disease (GvHD), and leukemia relapse after allogeneic HSCT in pediatric patients affected by hematological malignant and non-malignant disorders.
-
Carolyn Bertozzi
Baker Family Director of Sarafan ChEM-H, Anne T. and Robert M. Bass Professor in the School of Humanities and Sciences and Professor, by courtesy, of Chemical and Systems Biology
BioCarolyn Bertozzi is the Baker Family Director of Sarafan ChEM-H, Anne T. and Robert M. Bass Professor in the School of Humanities and Sciences and Professor, by courtesy, of Chemical and Systems Biology and of Radiology at Stanford University, and an Investigator of the Howard Hughes Medical Institute. She completed her undergraduate degree in Chemistry from Harvard University in 1988 and her Ph.D. in Chemistry from UC Berkeley in 1993. After completing postdoctoral work at UCSF in the field of cellular immunology, she joined the UC Berkeley faculty in 1996. In June 2015, she joined the faculty at Stanford University and became the co-director and Institute Scholar at Sarafan ChEM-H.
Prof. Bertozzi's research focuses on fundamental studies of disease-associated glycobiology and the development of new therapeutic modalities that target these pathways. Her inventions include bioorthogonal chemistries for in vivo imaging and bioconjugation, work for which she received the 2022 Nobel Prize in Chemistry. As well, her lab has developed next generation antibody-drug conjugates, lysosome-targeting chimeras (LYTACs), antibody-enzyme conjugates and antibody-lectin chimeras. Several of these new therapeutic modalities have been translated into clinical candidates for treatment of cancer and autoimmune diseases.
In addition to the Nobel Prize, Prof. Bertozzi has been recognized with many honors and awards for both her research and teaching accomplishments. For example, she is an elected member of the National Academy of Sciences, the National Academy of Medicine, the National Inventors Academy and the National Academy of Engineering, the American Academy of Arts and Sciences, the German Academy of Sciences Leopoldina, and she is a Foreign Fellow of the Royal Society. In addition, Prof. Bertozzi received the Priestley Medal of the American Chemical Society, the Welch Award, the Wolf Prize in Chemistry, the Heineken Prize, Lemelson-MIT award for inventors, and a MacArthur "Genius Award". -
Allison Betof, MD, PhD, FASCO
Associate Professor of Medicine (Oncology)
BioDr. Allison Betof is an Associate Professor of Medicine (Oncology), Director of the Melanoma Program, Director of Solid Tumor Cellular Therapy, and Mark & Mary Stevens Endowed Scholar in Melanoma at Stanford University School of Medicine. Dr. Betof completed her MD and PhD at Duke University, Internal Medicine residency at Massachusetts General Hospital (Harvard University) and Medical Oncology Fellowship at Memorial Sloan Kettering Cancer Center. Dr. Betof’s laboratory focuses on understanding resistance to immune checkpoint blockade and cellular therapies for melanoma and other solid tumors. She is the Principal Investigator of clinical trials exploring novel treatments for immunotherapy-refractory melanoma and is internationally recognized for her expertise in brain/CNS metastasis and the use of novel cellular therapies. Dr. Betof has been a pioneer in the use of commercial tumor infiltrating lymphocyte (TIL) therapy for the treatment of melanoma and other solid tumors. She has received funding and awards for her clinical and translational investigative work from multiple high-profile organizations, including the American Society of Clinical Oncology (ASCO), National Institutes of Health (NIH), Melanoma Research Alliance, and Melanoma Research Foundation.
